New xCas9 variant has higher specficity and broader PAM compatibility
Oxford based Nightstart to launch phase III clinical trial of gene therapy for choroideremia
MeirGTx recevies EMA PRIME designation for treatment of achromatopsia
AbbVie and Voyager Therapeutics to collaborate on gene therapy for Alzheimer's disease
FDA sets out path for stem cell therapies
The growing role of academia in clinical translation of gene and cell therapies
CRISPR, ready, go!!
A step towards treatment of congenital deafness with gene therapy
Treating allergy with a single vaccine?
Copyright ©2016 European Society for Gene and Cell Therapy | Website by OFEC